Matthew Luchini
Stock Analyst at BMO Capital
(0.76)
# 2,928
Out of 4,433 analysts
30
Total ratings
34.48%
Success rate
-5.69%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $6.81 | +340.53% | 1 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $21.60 | +779.63% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | n/a | $41.92 | - | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | n/a | $3.74 | - | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | n/a | $6.11 | - | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | n/a | $32.33 | - | 1 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $978.21 | - | 7 | Jan 25, 2021 | |
| BLUE bluebird bio | Downgrades: Market Perform | n/a | $1.07 | - | 5 | Nov 5, 2020 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Market Perform | n/a | $211.73 | - | 1 | Jun 5, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | n/a | $78.01 | - | 1 | Jun 5, 2020 | |
| GILD Gilead Sciences | Downgrades: Market Perform | n/a | $67.01 | - | 1 | Apr 20, 2020 | |
| LIFE aTyr Pharma | Maintains: Market Perform | n/a | $1.92 | - | 1 | Aug 15, 2018 | |
| RGLS Regulus Therapeutics | Maintains: Market Perform | n/a | $2.02 | - | 3 | Mar 8, 2018 | |
| BOLD Boundless Bio | Initiates: Outperform | n/a | $9.53 | - | 1 | Dec 5, 2017 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $6.81
Upside: +340.53%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $21.60
Upside: +779.63%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: n/a
Current: $41.92
Upside: -
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: n/a
Current: $3.74
Upside: -
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.11
Upside: -
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: n/a
Current: $32.33
Upside: -
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: n/a
Current: $978.21
Upside: -
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.07
Upside: -
Madrigal Pharmaceuticals
Jun 5, 2020
Initiates: Market Perform
Price Target: n/a
Current: $211.73
Upside: -
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: n/a
Current: $78.01
Upside: -
Gilead Sciences
Apr 20, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $67.01
Upside: -
aTyr Pharma
Aug 15, 2018
Maintains: Market Perform
Price Target: n/a
Current: $1.92
Upside: -
Regulus Therapeutics
Mar 8, 2018
Maintains: Market Perform
Price Target: n/a
Current: $2.02
Upside: -
Boundless Bio
Dec 5, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.53
Upside: -